PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30391799-8	2019	The altered molecular signaling pathways demonstrated the great potential of DFMT to overcome rituximab resistance resulting from either down-regulation of CD20 or endocytosis and trogocytosis of rituximab/CD20 complexes.	dfmt	77-81	keratin 20	Homo sapiens	156-160	
34361811-4	2021	Here, we intend to demonstrate that DFMT is a platform that will be effective on other receptors than previously validated CD20.	dfmt	36-40	keratin 20	Homo sapiens	123-127	
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	dfmt	156-160	keratin 20	Homo sapiens	96-100	
30391799-8	2019	The altered molecular signaling pathways demonstrated the great potential of DFMT to overcome rituximab resistance resulting from either down-regulation of CD20 or endocytosis and trogocytosis of rituximab/CD20 complexes.	dfmt	77-81	keratin 20	Homo sapiens	206-210	
30259654-1	2018	A therapeutic platform-drug-free macromolecular therapeutics (DFMT)-that induces apoptosis in B cells by cross-linking of CD20 receptors, without the need for low molecular weight cytotoxic drug, is developed.	dfmt	62-66	keratin 20	Homo sapiens	122-126	
30198798-3	2019	Without the need of low molecular weight drug, the hybridisation of morpholino oligonucleotide containing DFMT at NHL cell surface triggers CD20 crosslinking and subsequent apoptosis.	dfmt	106-110	keratin 20	Homo sapiens	140-144	
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	144-148	keratin 20	Homo sapiens	128-132	
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	144-148	keratin 20	Homo sapiens	128-132	
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	182-186	keratin 20	Homo sapiens	128-132	
30198798-6	2019	Compared with other cell cycle states, cells arrested at G2/M phase exhibit enhanced CD20 expression, and have more sustainable CD20 binding by DFMT, resulting in a higher degree of DFMT-mediated CD20 crosslinking.	dfmt	182-186	keratin 20	Homo sapiens	128-132	
30259654-7	2018	Selective surface binding of DFMT to CD20+ cells is validated in experiments on a coculture of CD20+ (Raji) and CD20-(DG-75) cells.	dfmt	29-33	keratin 20	Homo sapiens	37-41	
30259654-7	2018	Selective surface binding of DFMT to CD20+ cells is validated in experiments on a coculture of CD20+ (Raji) and CD20-(DG-75) cells.	dfmt	29-33	keratin 20	Homo sapiens	95-99	
30259654-7	2018	Selective surface binding of DFMT to CD20+ cells is validated in experiments on a coculture of CD20+ (Raji) and CD20-(DG-75) cells.	dfmt	29-33	keratin 20	Homo sapiens	95-99	
29595951-2	2018	Here, we apply drug-free macromolecular therapeutics (DFMT) that amplifies CD20 cross-linking to enhance apoptosis in RTX-resistant cells.	dfmt	54-58	keratin 20	Homo sapiens	75-79	
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	dfmt	172-176	keratin 20	Homo sapiens	114-118	
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	dfmt	172-176	keratin 20	Homo sapiens	114-118	
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	dfmt	172-176	keratin 20	Homo sapiens	29-33